Isoxazole and pyrazole derivatives as dopamine receptor subtype

Details Isoxazole and pyrazole derivatives as dopamine receptor subtype Isoxazole and pyrazole derivatives as dopamine receptor subtype

1996-05-14

1997-11-04

McKane, Joseph

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

514253, 544362, 544364, 544367, 544371, A61K 31495, C07D40106

Patent

active

056840063

DESCRIPTION:

BRIEF SUMMARY
This application is a filing under 35 USC 371 of PCT/GB94/02558, filed Nov. 21, 1994.
This invention relates to a particular class of substituted isoxazole and pyrazole derivatives which are ligands for dopamine receptor subtypes within the body and are therefore of use in the treatment and/or prevention of disorders of the dopamine system, including schizophrenia, depression, nausea, Parkinson's disease, tardive dyskinesias and extrapyramidal side-effects associated with treatment by conventional neuroleptic agents, neuroleptic malignant syndrome, and disorders of hypothalamic-pituitary function such as hyperprolactinaemia and amenorrhoea.
Upper gastrointestinal tract motility is believed to be under the control of the dopamine system. The compounds according to the present invention may thus be of use in the prevention and/or treatment of gastrointestinal disorders, and the facilitation of gastric emptying.
Dependence-inducing agents such as cocaine and amphetamine have been shown to interact with the dopamine. system. Compounds capable of counteracting this effect, including the compounds in accordance with the present invention, may accordingly be of value in the prevention or reduction of dependence on a dependence-inducing agent.
Dopamine is known to be a peripheral vasodilator; for example, it has been shown to exert a dilatory effect on the renal vascular bed. This implies that the compounds of the present invention may be beneficial in controlling vascular blood flow.
The localisation of dopamine receptor mRNA in rat heart and large vessels has been noted. This suggests a role for dopamine receptor ligands in controlling cardiovascular function, either by affecting cardiac and smooth muscle contractility or by modulating the secretion of vasoactive substances. The compounds according to the present invention may therefore be of assistance in the prevention and/or treatment of such conditions as hypertension and congestive heart failure.
Molecular biological techniques have revealed the existence of several subtypes of the dopamine receptor. The dopamine D.sub.1 receptor subtype has been shown to occur in at least two discrete forms. Two forms of the D.sub.2 receptor subtype, and at least one form of the D.sub.3 receptor subtype, have also been discovered. More recently, the D.sub.4 (Van Tol et al., Nature (London), 1991, 350, 610) and D.sub.5 (Sunahara et al., Nature (London), 1991, 350, 614) receptor subtypes have been described.
The compounds in accordance with the present invention, being ligands for dopamine receptor subtypes within the body, are accordingly of use in the treatment and/or prevention of disorders of the dopamine system.
The present invention accordingly provides a compound of formula I, or a salt thereof or a prodrug thereof: ##STR2## wherein the broken circle represents two non-adjacent double bonds whereby the five-membered ring containing X and Y is aromatic; oxygen or N-R.sup.5 ; heterocyclic group, halogen, cyano, trifluoromethyl, nitro, --OR.sup.a, --SR.sup.a, --SOR.sup.a, --SO.sub.2 R.sup.a, --SO.sub.2 NR.sup.a R.sup.b, --NR.sup.a R.sup.b, --NR.sup.a COR.sup.b, --NR.sup.a CO.sub.2 R.sup.b, --COR.sup.a, --CO.sub.2 R.sup.a or --CONR.sup.a R.sub.b ; heterocyclic group.
For use in medicine, the salts of the compounds of formula I will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof

REFERENCES:
patent: 5318970 (1994-06-01), Suzuki et al.
patent: 5338857 (1994-08-01), Ohto et al.
patent: 5342851 (1994-08-01), Sanfilippo et al.
Van Tol, et al. "Cloning of the Gene for a Human Dopamine D4 receptor with High Affinity for the Antipsychotic Clozapine" Nature vol. 350, Apr. 18, 1991 pp. 610-614.
Hawley's Condensed Chemical Dictionary, 11th Edition, 1987.

Affiliated with

Also associated with

Rating

Isoxazole and pyrazole derivatives as dopamine receptor subtype does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Isoxazole and pyrazole derivatives as dopamine receptor subtype , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoxazole and pyrazole derivatives as dopamine receptor subtype will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1833230